Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

V-ATPase G3 Activators

V-ATPase G3 Activators, such as Forskolin, IBMX, and 8-Br-cAMP, function through the activation of adenylate cyclase, which increases the levels of intracellular cAMP. These increased cAMP levels in turn activate Protein Kinase A (PKA), which phosphorylates and activates ATP6V1G3, enhancing V-ATPase activity. Some activators, including Bafilomycin A1 and Concanamycin A, function by inhibiting V-ATPase, which leads to an accumulation of protons in the cytosol. This triggers a compensatory response that includes the activation of ATP6V1G3.

Another group of activators, such as LY294002 and Rottlerin, act through the inhibition of other pathways, which leads to an upregulation of PKA activity and subsequent phosphorylation and activation of ATP6V1G3. In contrast, Okadaic acid and Calyculin A function by inhibiting protein phosphatases, such as PP1 and PP2A, which prevents the dephosphorylation of ATP6V1G3, maintaining its active state. Lastly, activators such as FTY720 and Zardaverine function by increasing cAMP levels through different mechanisms, leading to the activation of PKA and subsequent phosphorylation and activation of ATP6V1G3.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Forskolin

66575-29-9sc-3562
sc-3562A
sc-3562B
sc-3562C
sc-3562D
5 mg
50 mg
1 g
2 g
5 g
$78.00
$153.00
$740.00
$1413.00
$2091.00
73
(3)

Forskolin activates adenylate cyclase, increasing intracellular cAMP levels. The increased cAMP levels activate protein kinase A (PKA), which phosphorylates and activates ATP6V1G3, enhancing V-ATPase activity.

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$260.00
$350.00
$500.00
34
(1)

IBMX is a non-specific phosphodiesterase inhibitor, leading to increased cAMP levels. Elevated cAMP activates PKA, which phosphorylates and activates ATP6V1G3.

8-Bromo-cAMP

76939-46-3sc-201564
sc-201564A
10 mg
50 mg
$126.00
$328.00
30
(1)

8-Br-cAMP is a cell-permeable cAMP analog. By directly increasing cAMP levels, it activates PKA, leading to the phosphorylation and activation of ATP6V1G3.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$98.00
$255.00
$765.00
$1457.00
280
(6)

Bafilomycin A1 inhibits V-ATPase reversibly. This results in an accumulation of protons in the cytosol, which can stimulate a compensatory response leading to the activation of ATP6V1G3.

Concanamycin A

80890-47-7sc-202111
sc-202111A
sc-202111B
sc-202111C
50 µg
200 µg
1 mg
5 mg
$66.00
$167.00
$673.00
$2601.00
109
(2)

Like Bafilomycin A1, Concanamycin A inhibits V-ATPase, leading to increased cytosolic proton concentration. This can trigger a compensatory response, activating ATP6V1G3.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 inhibits PI3K, leading to decreased Akt activity. This can lead to an upregulation of PKA activity, which phosphorylates and activates ATP6V1G3.

Okadaic Acid

78111-17-8sc-3513
sc-3513A
sc-3513B
25 µg
100 µg
1 mg
$291.00
$530.00
$1800.00
78
(4)

Okadaic acid is a potent inhibitor of protein phosphatase 1 (PP1) and 2A (PP2A). By preventing dephosphorylation, it maintains the phosphorylated (active) state of ATP6V1G3.

Calyculin A

101932-71-2sc-24000
sc-24000A
10 µg
100 µg
$163.00
$800.00
59
(3)

Calyculin A is a potent inhibitor of protein phosphatases, such as PP1 and PP2A. By inhibiting these phosphatases, it maintains the phosphorylated, active state of ATP6V1G3.

FTY720

162359-56-0sc-202161
sc-202161A
sc-202161B
1 mg
5 mg
25 mg
$33.00
$77.00
$120.00
14
(1)

FTY720 is a sphingosine 1-phosphate receptor modulator. Its action leads to the activation of adenylate cyclase, increasing cAMP levels, and subsequently activating ATP6V1G3 via PKA.

Rottlerin

82-08-6sc-3550
sc-3550B
sc-3550A
sc-3550C
sc-3550D
sc-3550E
10 mg
25 mg
50 mg
1 g
5 g
20 g
$84.00
$166.00
$302.00
$2091.00
$5212.00
$16657.00
51
(2)

Rottlerin is a PKC delta inhibitor. Its action can shift the cellular balance towards PKA activity, leading to increased phosphorylation and activation of ATP6V1G3.